|Bid||287.80 x N/A|
|Ask||287.80 x N/A|
|Day's range||275.90 - 289.00|
|52-week range||241.17 - 337.40|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||17.90|
|Earnings date||20 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||328.33|
The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years
The company, which owns health products Sensodyne and Panadol, posted a 13.4% rise in its revenue to £5.2 billion in the first half of the year.
LONDON (Reuters) -Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday. Zantac, originally marketed by a forerunner of GSK , has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers. Haleon, spun out of GSK as an independent company in July as the world's biggest standalone consumer health business, comprises consumer health assets once owned by GSK and Pfizer.